Matches in SemOpenAlex for { <https://semopenalex.org/work/W4205122100> ?p ?o ?g. }
- W4205122100 endingPage "465" @default.
- W4205122100 startingPage "455" @default.
- W4205122100 abstract "Aim. The observational program was aimed at obtaining data on classical Hodgkin's lymphoma (cHL) incidence in the Russian Federation, therapy options, and clinical outcomes of treatment. The aim of the prospective part of the program was to standardize the approaches to therapy and to compare its outcomes with off-protocol treatment. Materials & Methods. The prospective-retrospective observational program for Hodgkin's lymphoma treatment engaged 32 regional and federal centers. It included 218 patients, 21 out of them were included into the prospective part of the RNWOHG-HD1 (Russian North-West Oncology and Hematology Group - Hodgkin Disease Study 1) program. The median age was 36 years (range 22-87 years). cHL stages I/II were identified in 48 % of patients, III/IV stages were reported in 52 % of patients. The prospective part of the program used escalating protocol in patients with stages I/IIA and without risk factors and de-escalating protocol in patients with advanced stages. Overall (OS) and progression-free (PFS) survivals were analyzed in 160 and 152 patients, respectively. PET-CT was used to assess the response in 33 % of patients. Results. The study used the following first-line chemotherapy regimens: ABVD in 42 %, BEACOPPst in 11 %, BEACOPP-14 in 17 %, BEACOPPesc in 25 %, and EACOPP in 1 % of cases. After the completion of first-line therapy objective response rate was 91 % including 61 % of complete responses. Response structure did not significantly differ in the groups of non-intensive therapy (ABVD and BEACOPPst), intensified regimens (BEACOPP-14, BEACOPPesc, and EACOPP), and treatment according to the RNWOHG-HD1 protocol (91 %, 92 %, and 96 %, respectively; p = 0.7226). In the total cohort the 3-year OS was 97 % (95% confidence interval [95% CI] 94-99 %), PFS was 87 % (95% CI 80-92 %). The 3-year PFS did not differ in ABVD, BEACOPPst, BEACOPP-14, BEACOP-Pesc, and RNWOHG-HD1 recipients (р = 0.37). International Prognostic Score (IPS) yielded significant results in PFS prediction for patients with IPS score of 5-6, but not for those with IPS score of 1-4 (p = 0.0028). Conclusion. The observational program showed that the majority of participating centers use the risk-adapted ABVD/ BEACOPPesc approach which explains no difference in PFS being found with the use of these chemotherapy options. The study demonstrated the need for PET-CT to assess the response since the CT alone cannot distinguish between complete and partial responses in a considerable number of patients. The prospective unified program for cHL treatment may well be implemented in the Russian Federation." @default.
- W4205122100 created "2022-01-26" @default.
- W4205122100 creator A5000204350 @default.
- W4205122100 creator A5002109641 @default.
- W4205122100 creator A5003058937 @default.
- W4205122100 creator A5016336792 @default.
- W4205122100 creator A5016454960 @default.
- W4205122100 creator A5016972232 @default.
- W4205122100 creator A5020670254 @default.
- W4205122100 creator A5023744424 @default.
- W4205122100 creator A5027665152 @default.
- W4205122100 creator A5030235127 @default.
- W4205122100 creator A5031410374 @default.
- W4205122100 creator A5035475547 @default.
- W4205122100 creator A5042189318 @default.
- W4205122100 creator A5044776670 @default.
- W4205122100 creator A5049805051 @default.
- W4205122100 creator A5050649705 @default.
- W4205122100 creator A5058956866 @default.
- W4205122100 creator A5059723473 @default.
- W4205122100 creator A5061938086 @default.
- W4205122100 creator A5065887741 @default.
- W4205122100 creator A5070314481 @default.
- W4205122100 creator A5071610128 @default.
- W4205122100 creator A5071686029 @default.
- W4205122100 creator A5072006273 @default.
- W4205122100 creator A5073056505 @default.
- W4205122100 creator A5084330987 @default.
- W4205122100 creator A5085881607 @default.
- W4205122100 creator A5086770406 @default.
- W4205122100 creator A5087183847 @default.
- W4205122100 creator A5089388229 @default.
- W4205122100 creator A5089717381 @default.
- W4205122100 creator A5091038445 @default.
- W4205122100 creator A5091628280 @default.
- W4205122100 date "2021-01-01" @default.
- W4205122100 modified "2023-10-16" @default.
- W4205122100 title "Results of the Russian Multi-Center Cooperative Prospective-Retrospective Observational Program for Hodgkin’s Lymphoma Treatment RNWOHG-HD1" @default.
- W4205122100 cites W1753364174 @default.
- W4205122100 cites W1893048570 @default.
- W4205122100 cites W1973535185 @default.
- W4205122100 cites W2001292073 @default.
- W4205122100 cites W2058383365 @default.
- W4205122100 cites W2067799640 @default.
- W4205122100 cites W2101873015 @default.
- W4205122100 cites W2103004443 @default.
- W4205122100 cites W2105604016 @default.
- W4205122100 cites W2119147717 @default.
- W4205122100 cites W2136962826 @default.
- W4205122100 cites W2137965731 @default.
- W4205122100 cites W2140801657 @default.
- W4205122100 cites W2142880562 @default.
- W4205122100 cites W2165308914 @default.
- W4205122100 cites W2342440786 @default.
- W4205122100 cites W2469052042 @default.
- W4205122100 cites W2570618306 @default.
- W4205122100 cites W2587075966 @default.
- W4205122100 cites W2775803967 @default.
- W4205122100 cites W2784350383 @default.
- W4205122100 cites W2909797130 @default.
- W4205122100 cites W3021443408 @default.
- W4205122100 cites W3023412939 @default.
- W4205122100 cites W3089986529 @default.
- W4205122100 cites W3126958490 @default.
- W4205122100 cites W4298131646 @default.
- W4205122100 doi "https://doi.org/10.21320/2500-2139-2021-14-4-455-465" @default.
- W4205122100 hasPublicationYear "2021" @default.
- W4205122100 type Work @default.
- W4205122100 citedByCount "1" @default.
- W4205122100 countsByYear W42051221002022 @default.
- W4205122100 crossrefType "journal-article" @default.
- W4205122100 hasAuthorship W4205122100A5000204350 @default.
- W4205122100 hasAuthorship W4205122100A5002109641 @default.
- W4205122100 hasAuthorship W4205122100A5003058937 @default.
- W4205122100 hasAuthorship W4205122100A5016336792 @default.
- W4205122100 hasAuthorship W4205122100A5016454960 @default.
- W4205122100 hasAuthorship W4205122100A5016972232 @default.
- W4205122100 hasAuthorship W4205122100A5020670254 @default.
- W4205122100 hasAuthorship W4205122100A5023744424 @default.
- W4205122100 hasAuthorship W4205122100A5027665152 @default.
- W4205122100 hasAuthorship W4205122100A5030235127 @default.
- W4205122100 hasAuthorship W4205122100A5031410374 @default.
- W4205122100 hasAuthorship W4205122100A5035475547 @default.
- W4205122100 hasAuthorship W4205122100A5042189318 @default.
- W4205122100 hasAuthorship W4205122100A5044776670 @default.
- W4205122100 hasAuthorship W4205122100A5049805051 @default.
- W4205122100 hasAuthorship W4205122100A5050649705 @default.
- W4205122100 hasAuthorship W4205122100A5058956866 @default.
- W4205122100 hasAuthorship W4205122100A5059723473 @default.
- W4205122100 hasAuthorship W4205122100A5061938086 @default.
- W4205122100 hasAuthorship W4205122100A5065887741 @default.
- W4205122100 hasAuthorship W4205122100A5070314481 @default.
- W4205122100 hasAuthorship W4205122100A5071610128 @default.
- W4205122100 hasAuthorship W4205122100A5071686029 @default.
- W4205122100 hasAuthorship W4205122100A5072006273 @default.
- W4205122100 hasAuthorship W4205122100A5073056505 @default.
- W4205122100 hasAuthorship W4205122100A5084330987 @default.
- W4205122100 hasAuthorship W4205122100A5085881607 @default.